SEC Filings

Form 8-K
PROTAGONIST THERAPEUTICS, INC filed this Form 8-K on 10/13/2017
Document Outline
Entire Document (711.3 KB)
Subdocument 1 - 8-K - 8-K
Page 2 - Item 8.01. Other Events.
Subdocument 2 - EX-1.1 - EX-1.1
Page 1 - Exhibit 1.1
Page 2 - Rule 430B
Page 3 - 1934 Act
Page 4 - Accurate Disclosure
Page 5 - Schedule B-2
Page 6 - Sarbanes-Oxley Act of 2002
Page 7 - Capitalization
Page 8 - Agreements and Instruments
Page 9 - Accuracy of Exhibits
Page 10 - Patents and Patent Applications
Page 11 - Health Care Laws
Page 12 - Environmental Laws
Page 13 - Payment of Taxes
Page 14 - Absence of Manipulation
Page 15 - Statistical and Market-Related Data
Page 16 - Payment
Page 17 - Continued Compliance with Securities Laws
Page 18 - Blue Sky Qualifications
Page 19 - Reporting Requirements
Page 20 - Emerging Growth Company Status
Page 21 - Effectiveness of Registration Statement
Page 22 - Approval of Listing
Page 23 - Termination of Agreement
Page 24 - Indemnification of Company, Directors and Officers
Page 25 - Schedule A
Page 26 - Representations, Warranties and Agreements to Survive
Page 27 - Notices
Page 28 - Waiver of Trial by Jury
Page 29 - Schedule A
Page 30 - Schedule A
Page 31 - N/A
Page 32 - Pricing Terms
Page 33 - Free Writing Prospectuses
Page 34 - List of Written Testing-the-Waters Communications
Page 35 - Proposed Public Offering by Protagonist Therapeutics, Inc.
Page 36 - bona fide
Page 37 - N/A
Page 38 - Very truly yours, IF AN INDIVIDUAL:
Subdocument 3 - EX-5.1 - EX-5.1
Page 1 - Exhibit 5.1
Page 2 - We hereby consent to the reference to our firm under the caption Legal Matters in the Prospectus and
Subdocument 4 - EX-99.1 - EX-99.1
Page 1 - Exhibit 99.1
Page 2 - We are an early clinical-stage biopharmaceutical company with no approved products and no historical
Page 3 - We will require substantial additional funding, which may not be available to us on acceptable terms
Page 4 - N/A
Page 5 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 6 - N/A
Page 7 - If Janssen does not elect to continue the development of PTG-200 through an Opt-In Election, our bus
Page 8 - N/A
Page 9 - Clinical development is a lengthy and expensive process with an uncertain outcome, and results of ea
Page 10 - Enrollment and retention of patients in clinical trials is an expensive and time-consuming process a
Page 11 - Our research and development strategy for our lead product candidates relies in large part on clinic
Page 12 - Our product candidates may cause undesirable side effects or have other properties impacting safety
Page 13 - We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third par
Page 14 - We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance
Page 15 - We may fail to obtain orphan drug designations from the FDA for our product candidates, as applicabl
Page 16 - We may not be successful in obtaining or maintaining development and commercialization collaboration
Page 17 - We face significant competition from other biotechnology and pharmaceutical companies, and our opera
Page 18 - We have not yet negotiated our agreement with Janssen specifying all of the terms of our Co-Detailin
Page 19 - We currently have no marketing and sales organization. To the extent any of our peptide-based produc
Page 20 - We have focused our limited resources to pursue particular product candidates and indications, and c
Page 21 - If we fail to comply with state and federal healthcare regulatory laws, we could face substantial pe
Page 22 - N/A
Page 23 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 24 - N/A
Page 25 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 26 - We will need to expand the size of our organization, and we may experience difficulties in managing
Page 27 - Our insurance policies are expensive and only protect us from some business risks, which will leave
Page 28 - Our employees, independent contractors, principal investigators, consultants and vendors may engage
Page 29 - We currently conduct, and intend to continue to conduct a substantial portion of the clinical trials
Page 30 - Our headquarters and certain of our data storage facilities are located near known earthquake fault
Page 31 - Risks Related to Our Intellectual Property
Page 32 - N/A
Page 33 - N/A
Page 34 - We may be involved in lawsuits to protect or enforce our intellectual property, which could be expen
Page 35 - The lives of any patents issued as a result of our pending or future patent applications may not be
Page 36 - Third party claims of intellectual property infringement may prevent or delay our drug discovery and
Page 37 - We may not identify relevant third party patents or may incorrectly interpret the relevance, scope o
Page 38 - Because of the expense and uncertainty of litigation, we may not be in a position to enforce our int
Page 39 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
Page 40 - Intellectual property rights do not necessarily address all potential threats to our competitive adv
Page 41 - We may be subject to claims challenging the inventorship or ownership of our issued patents, any pat
Page 42 - We have not yet registered trademarks for a commercial trade name for our product candidates and fai
Page 43 - Risks Related to Ownership of our Common Stock
Page 44 - N/A
Page 45 - Volatility in our share price could subject us to securities class action litigation.
Page 46 - We are obligated to develop and maintain proper and effective internal controls over financial repor
Page 47 - We are an emerging growth company and as a result of the reduced disclosure and governance requireme
Page 48 - If we sell shares of our common stock in future financings, stockholders may experience immediate di
Page 49 - NASDAQ may delist our securities from its exchange, which could limit investors ability to make tran
Page 50 - Claims for indemnification by our directors and officers may reduce our available funds to satisfy s
Page 51 - Our amended and restated certificate of incorporation provides that the Court of Chancery of the Sta
Page 52 - Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be